Last reviewed · How we verify
Vyxeos
At a glance
| Generic name | Vyxeos |
|---|---|
| Also known as | daunorubicin-cytarabine, CPX-351, cpx-351, cytarabine and daunorubicin liposome, CPX-351 |
| Sponsor | H. Lee Moffitt Cancer Center and Research Institute |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS • VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors [see Warnings and Precautions ( 5.1 )] . WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS See
Common side effects
- Hemorrhage
- Febrile Neutropenia
- Rash
- Edema
- Nausea
- Diarrhea/Colitis
- Mucositis
- Constipation
- Musculoskeletal pain
- Abdominal pain
- Cough
- Headache
Serious adverse events
- Pneumonia
- Dyspnea
- Hemorrhage
- Arrhythmia
- Fatigue
- Myocardial toxicity
- Sepsis
- Bacteremia
- Febrile Neutropenia
- CNS hemorrhage
Key clinical trials
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) (PHASE2)
- Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (PHASE2)
- Phase IB/II of CPX-351 for Relapse Prevention in AML (PHASE1, PHASE2)
- Tazemetostat and Palbociclib With CPX-351for R/R AML (PHASE1)
- Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia (PHASE2)
- CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia (PHASE2)
- CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vyxeos CI brief — competitive landscape report
- Vyxeos updates RSS · CI watch RSS
- H. Lee Moffitt Cancer Center and Research Institute portfolio CI